Appendix B: Scopes for NICE clinical guideline update 2015, NICE clinical guideline 117 & NICE clinical guideline 33

1 Guideline title

Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (update)

1.1 Short title

Tuberculosis

2 The remit

The Department of Health has asked NICE: To prepare guidance for the NHS in England and Wales on the clinical management and diagnosis of, and measures to prevent and control tuberculosis (TB). This will replace the current guideline, ‘Tuberculosis’ (NICE clinical guideline 117).

This is an update of ‘Tuberculosis’ (NICE clinical guideline 117). See section 5.3.1 for details of which sections will be updated. We will also carry out an editorial review of all recommendations to ensure that they comply with NICE’s duties under equalities legislation.

This update is being undertaken as part of the guideline review cycle.

In addition to updating NICE clinical guideline 117, this guidance will aim to incorporate recommendations from ‘Tuberculosis - hard-to-reach groups’ (NICE public health guidance 37), where possible.

3 Background

Activities related to the diagnosis, management, prevention and control of TB are undertaken in both clinical and public health settings by a range of different practitioners. These different audiences share the same need for evidence-based, cost-effective solutions to the challenges in their day-to-day practice, as well as to inform policies and strategies to improve health.

This guidance will be produced using the Centre for Clinical Practice's standard process, using a single Guidance Development Group with expertise across clinical
and public health practice. In addition to the clinical areas identified in the scope, the Centre for Public Health Excellence at NICE will develop a series of public health evidence reviews to inform additional recommendations in relevant areas.

4 Need for the guidance

4.1 Epidemiology

a) Tuberculosis (TB) is an infectious disease caused by the bacterium *Mycobacterium tuberculosis*. TB most commonly affects the lungs (respiratory TB) but can also affect other parts of the body. In the UK in 2011, more than half of reported cases (52%) were respiratory TB.

b) The symptoms of TB are varied and depend on the site of infection, although general symptoms may include fever, loss of appetite, weight loss, night sweats and tiredness. Respiratory TB typically causes a persistent cough that may be accompanied by blood-streaked sputum or, more rarely, expectoration of blood only.

c) Almost all cases of TB in the UK are contracted when a person breathes in infected respiratory droplets from a person with active respiratory TB. The initial infection may:

- be eliminated by the body, or
- remain clinically latent; the person has no symptoms but the TB bacteria remain in the body, or progress to active TB over the following weeks or months; in some cases it can take many years for a person to develop active TB.

d) According to the World Health Organization, people with active TB can infect up to 15 other people through close contact over the course of a year. The risk of becoming infected depends principally on how long and how intense the exposure to the bacterium is. People infected with TB bacteria subsequently have a lifetime risk of progressing to active respiratory TB of about 10%, with the highest risk occurring in the first few years after infection. The risk of progressing to the active disease can be much higher in groups such as children, older people, people who are
immunocompromised, and people with chronic poor health. For example, people who are co-infected with HIV and TB that are not treated are 21 to 34 times more likely to develop active TB; this risk is lower in those receiving antiretroviral therapy. Detection of latent TB is therefore important in controlling the incidence of disease.

e) In England, rates of TB had fallen progressively until the mid-1980s but started to rise again in the early 1990s. In 2011 in the UK, the Health Protection Agency (HPA) reported a total of 8963 cases of TB (an increase of 31% from 2001) at a rate of 14.4 cases per 100,000 (an increase of 26% from 2001). In a 12-month period between 2010 and 2011, 436 people reported to have TB died (5% of the 8171 people for whom outcome data was available).

f) The majority of TB cases recorded in 2011 were in urban areas, and occurred in young adults, people from countries with a high incidence of TB and people with social risk factors for TB, including a history of substance misuse, homelessness or a history of imprisonment.

g) Many cases of TB can be prevented by public health measures and when clinical disease does occur, most people can be cured if treated properly. It is vital that all medication is taken as prescribed. Taking medication in the wrong dose or combination, irregularly or for too short a time can lead to drug resistance. Drug-resistant strains of TB are much harder to treat and significantly increase a person's risk of long-term complications or death.

h) According to the HPA, strains of TB that are resistant to at least isoniazid and rifampicin, two of the first-line drugs used in the treatment of TB, are known as multidrug-resistant (MDR) TB. MDR-TB that is also resistant to any one of a group of broad-spectrum antibiotics called fluoroquinolones and at least one of three injectable second-line anti-TB drugs (capreomycin, kanamycin or amikacin) is known as extensively drug-resistant TB (XDR-TB).
In 2011, there were increases in the proportion of cases resistant to isoniazid (from 6% in 2010 to 8%), cases resistant to any first-line drug (7% in 2010 to 8%), and cases resistant to multiple drugs (from 1% in 2010 to 2%). In addition, 58% (47/81) of MDR-TB cases were resistant to at least one second-line drug.

Drug-resistant TB is most commonly found in people born outside the UK and in those with social risk factors for TB, including a history of substance misuse, homelessness or a history of imprisonment.

4.2 Current practice

a) NICE clinical guideline 117 (‘Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control’) and NICE public health guidance 37 (‘Identifying and managing tuberculosis among hard-to-reach groups’), represent the current standards for TB diagnosis, management and prevention in England and Wales.

b) Clinical suspicion of TB may arise from a combination of context, symptoms, clinical signs and investigations. The diagnosis is rarely made from a single piece of evidence, and the sensitivity and specificity of individual tests may not reflect the strength of multiple tests or data.

c) When a person presents with a suspected case of active respiratory TB, a chest X-ray is taken. If the X-ray is suggestive of TB, multiple sputum samples will be sent for TB microscopy and culture. Treatment of active respiratory TB is with a combination of antibiotics; the ‘standard recommended regimen’ consists of:

- isoniazid and rifampicin: every day for 6 months
- two additional antibiotics, pyrazinamide and ethambutol: every day for the first 2 months.

d) When a person presents with suspected active TB outside the lungs, several tests can be used to confirm a diagnosis. These include a variety of radiological and laboratory tests, the combination of which will depend
on the suspected site of the infection. Treatment of non-respiratory TB generally uses the same regimen of antibiotics as for respiratory TB. However, in people with suspected involvement of the nervous system, a 12-month rather than a 6-month course is used. Additionally, a 2–3-week course of corticosteroids may also be prescribed for people with suspected heart or nervous system involvement.

e) All people diagnosed with active TB undergo a risk assessment for drug resistance, and those at increased risk are closely monitored for their response to treatment. If the risk is regarded as significant, rapid diagnostic tests for drug resistance may be used to confirm the presence of drug-resistant TB. Drug-resistant TB is treated with various combinations of antibiotics, depending on the type of resistance present.

f) Mantoux tests and/or interferon-gamma testing are used to diagnose latent TB. These tests are performed as part of contact-tracing initiatives following the diagnosis of a case of active TB or as part of case-finding programmes among high-risk groups. Treatment for latent TB is usually recommended for:

- people who are 35 years or younger
- people with HIV, regardless of their age
- healthcare workers, regardless of their age
- people with evidence of scarring caused by TB, as shown on a chest X-ray, but who were not adequately treated.

Different regimens of antibiotics are prescribed to treat latent TB depending on the age of the person, their HIV status and whether or not they are a contact of someone with drug-resistant TB.

g) Directly observed therapy (DOT) is widely used to promote adherence to treatment regimens. It is standard care for people who request it, or for those who:

- represent a particular risk for non-adherence to treatment or
- are unable to administer the treatment themselves or
- are currently (or have previously been) in prison or
• have MDR-TB.

h) With the increases in drug resistance observed in the UK over the last few years, and the treatment difficulties and risks to both patients and the wider population that this entails, there is a need to ensure that people with TB are identified, and their disease is managed, in a timely and effective manner.

5 The guidance

The guidance development process is described in detail on the NICE website (see section 6, `Further information`).

This scope defines what the guidance will (and will not) examine, and what the guidance developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guidance are described in the following sections.

5.1 Population

5.1.1 Groups that will be covered

a) Adults, young people and children who have, or who are suspected to have, active TB caused by *Mycobacterium tuberculosis* complex (*M. tuberculosis*, *M. africanum*, *M. bovis*).

b) Adults, young people and children who have latent infection with *Mycobacterium tuberculosis* complex, but not active disease.

c) Adults, young people and children at increased risk of infection with *Mycobacterium tuberculosis* complex and/or at increased risk of progressing to the active disease.

d) Consideration will also be given to specific subgroups for whom the diagnosis and management of TB may vary. These may include, but are not limited to:
Appendix B: Guideline scopes

- neonates, children and young people
- adults older than 35 years
- people with HIV and other comorbidities or conditions that impact on the diagnosis and management of TB.

e) Both drug-susceptible and drug-resistant strains of *Mycobacterium tuberculosis* complex will be considered.

5.1.2 Groups that will not be covered

a) People with other mycobacterial infections, for example *M. leprae, M. avium* complex and other opportunistic mycobacteria.

b) People at risk of contracting *Mycobacterium bovis* from animals, including cattle.

5.2 Setting

a) Any setting in which NHS or public health services for TB are received, provided or commissioned in the public, private and voluntary sectors.

5.3 Topics of interest

5.3.1 Key issues that will be covered

Areas from the original guidelines (‘Tuberculosis’ [NICE clinical guideline 117]) that will be updated by an evidence review

Areas to be developed by the Centre for Clinical Practice

a) Diagnosis of active respiratory and non-respiratory TB, including:

- clinical suspicion of disease
- radiological patterns
- microscopy and culture techniques
- biopsy
- interferon-gamma release assays
- rapid diagnostics, including molecular assays.

b) Treatment of active TB. Specific consideration will be given to when treatment should deviate from the 'standard recommended regimen',
taking into account factors such as the site and severity of the disease, and individual patient characteristics including age and the presence of comorbidities such as HIV, renal or liver disease and drug dependency. Alterations to the standard recommended regimen might include:

- dose frequency
- duration of treatment
- the use of adjunctive treatments, including corticosteroids and surgery.

c) Identification of multiple drug resistance and isolated and combined resistances, including:

- risk factors
- microbiological drug susceptibility testing
- rapid diagnostics.

d) Treatment of drug-resistant TB (excluding MDR- or XDR-TB).

e) General principles for the management of drug resistance.

f) Response to treatment interruptions.

g) Infection control measures to ensure that people with infectious, active TB (including drug-resistant TB) do not infect others.

h) Diagnosis of latent TB infection using Mantoux testing and interferon-gamma release assays in:

- children
- people who are immunocompromised, such as people with HIV or renal disease, or at known risk of immunosuppression, such as people about to start immunosuppressive regimens
- new entrants from high incidence countries, in the context of opportunistic case-finding rather than proactive screening programmes.

i) Treatment of latent TB infection. Including:

- isoniazid
- rifampicin.
j) Note that for pharmacological interventions recommendations will normally fall within licensed indications; exceptionally and only where clearly supported by evidence, use outside of a licensed indication may be recommended. The guidance will assume that prescribers will use the Summary of Product Characteristics to inform their decisions for individual patients.

Areas to be developed by the Centre for Public Health Excellence
k) Encouraging uptake of BCG vaccination among people at increased risk of developing active or latent TB.

l) Promoting the uptake of, and improving adherence to, treatment for people with active and latent TB.

Areas not in the original guideline that will be included in the update by the Centre for Public Health Excellence
m) Provision of education, information and support for people with TB, their families and carers, and healthcare workers across the care pathway (from diagnosis to follow-up after completion of treatment).

Areas not in the original guideline that will be included in the update using the Centre for Clinical Practice’s interim methods for developing service delivery guidance

This question will be addressed by the Centre for Public Health Excellence using the Centre for Clinical Practice’s interim methods for developing service delivery guidance. A subgroup of the Guideline Development Group, plus additional experts, will be used for this question.

n) Organisation and management of clinical and public health TB services.

5.3.2 Issues that will not be covered

Areas from the original guideline that will not be updated by an evidence review (recommendations from CG117 will appear in the final guidance)
a) Diagnosis of active respiratory TB, in terms of:

- the symptoms suggestive of a diagnosis of respiratory TB
- the number of sputum samples required for an accurate diagnosis
approaches to collecting sputum samples in adults unable to expectorate spontaneously.

b) Treatment of active TB, in terms of:

- the combination of anti-TB drugs used for people both with and without HIV co-infection, except where related to drug interactions
- the frequency of dosing in adults both with and without HIV co-infection
- the use of combination formulations, where available, for any drug-susceptible or drug-resistant disease.

c) Monitoring of patients after treatment completion.

Diagnosis of latent infection for groups other than those listed in 5.3.1h.

Occupational health measures to prevent the transmission of TB in the workplace.

Effectiveness of BCG vaccination.

**Areas not covered by the original guidelines or the update**

Interventions to address the social determinants of risk, except where they relate directly to the diagnosis, management, prevention or control of TB.

**Areas covered by the original guidelines that will not be included in the update**

New entrant screening programmes.

**5.4 Main outcomes**

Main outcomes to be considered include:

a) Diagnosis:

- diagnostic utility and accuracy
- time to diagnosis or treatment initiation
- prognostic value of tests
- acceptability of approach
- adverse events
- health-related quality of life
- resource use and cost.
b) Treatment:

- mortality
- adverse events
- adherence and treatment completion
- treatment success and rate of recovery, or treatment failure, relapse and emergence of drug resistance
- health-related quality of life
- resource use and cost.

c) Infection control:

- TB transmission rate
- acceptability of approach
- health-related quality of life
- resource use and cost.

d) Promoting the uptake of, and improving adherence to, treatment, including:

- uptake and completion of treatment
- acceptability of approach
- direct and indirect measures of adherence (for example, direct observation of people taking their medication and self-reported medication taking)
- barriers to uptake and adherence to treatment.

e) BCG vaccination uptake in at-risk groups:

- uptake of BCG vaccination
- barriers to uptake.

f) Information, education and support:

- knowledge and awareness of TB among people who have, or who are at high-risk from TB and relevant staff, including how to recognise symptoms, the need for rapid diagnosis, referral and access to specialist TB services, and the need for prompt, complete treatment
• health, social and economic outcomes for people affected by TB.

5.5 Draft review questions

Review questions guide a systematic review of the literature. They address only the key clinical issues covered in the scope, and usually relate to interventions, diagnosis, prognosis, service delivery or patient experience. Please note that these review questions are draft versions and will be finalised with the Guideline Development Group.

5.5.1 Areas to be developed by the Centre for Clinical Practice

Diagnosis of active TB

Respiratory TB

a) What are the most effective methods for (i) sputum smear microscopy and (ii) sputum culture in establishing an accurate diagnosis of active respiratory TB?

k) What is the most effective method of collecting sputum samples from children unable to expectorate spontaneously?

l) While awaiting culture results in adults with suspected respiratory TB, what other tests are effective in establishing an accurate diagnosis of active respiratory TB?

m) While awaiting culture results in children and young people with suspected respiratory TB, what other tests are effective in establishing an accurate diagnosis of active respiratory TB?

n) In the presence of a negative culture, what other tests may support an accurate, positive diagnosis in people with suspected respiratory TB?

Non-respiratory TB

o) What clinical signs, symptoms or risk factors are suggestive of a diagnosis of active non-respiratory TB? (note: analysis will be conducted by site of disease)

p) While awaiting culture results in people with suspected non-respiratory TB, what other tests are effective in establishing an accurate diagnosis of
Appendix B: Guideline scopes

active non-respiratory TB? (note: analysis will be conducted by site of disease)

q) In the presence of a negative culture, what other tests may support an accurate, positive diagnosis in people with suspected non-respiratory TB? (note: analysis will be conducted by site of disease)

Treatment of active TB

r) In children with active TB receiving drug treatment, are intermittent dosing regimens as effective as daily drug treatment regimens in reducing mortality and morbidity?

s) In people co-infected with TB and HIV receiving drug treatment for both infections, what are the key pharmacological considerations that should be taken into account when selecting a treatment regimen for eradicating TB infection?

t) What comorbidities or conditions affect the choice of regimen for the treatment of TB? How should the standard recommended regimen be adapted to accommodate these comorbidities or conditions?

Respiratory TB

u) In adults with active respiratory TB receiving drug treatment, are there particular circumstances in which a treatment period longer than 6 months would provide an additional benefit in terms of reducing mortality and morbidity? What duration of treatment is appropriate in these patients?

v) In children with active respiratory TB receiving drug treatment, is the standard recommended regimen of 6 months effective in reducing mortality and morbidity? Are there circumstances in which a longer treatment period is indicated?

w) In people with active respiratory TB receiving drug treatment, do corticosteroids (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone?
x) In people with active respiratory TB receiving drug treatment, does surgery (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone?

**Non-respiratory TB**

y) In people with active non-respiratory TB receiving drug treatment, is the standard recommended regimen of 6 months effective in reducing mortality and morbidity? Are there circumstances in which a longer treatment period is indicated? (note: analysis will be conducted by site of disease)

z) In people with active non-respiratory TB, do corticosteroids (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone? (note: analysis will be conducted by site of disease)

aa) In people with active non-respiratory TB, does surgery (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone? (note: analysis will be conducted by site of disease)

**Identification of drug-resistant TB**

bb) In people with suspected or confirmed active TB, which relative risk factors are associated with a higher level of: i) multidrug resistance, or ii) any drug resistance?

cc) Other than review of a patient’s risk factors for drug resistance, what diagnostic methods should be used for the identification of drug resistance?

**Treatment of drug-resistant TB**

dd) In people with drug-resistant TB (excluding MDR- and XDR-TB), i) what is the most effective combination of anti-TB drugs for reducing mortality and morbidity? ii) What is the most effective duration of treatment? (note: analysis will be conducted by type of resistance)
ee) In people with drug-resistant TB, are intermittent dosing regimens as effective as daily drug treatment regimens in reducing mortality and morbidity?

ff) In people with drug-resistant TB, do corticosteroids (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone?

gg) In people with drug-resistant TB, does surgery (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and mortality compared with an anti-TB drug regimen alone?

**General principles for the management of drug resistance**

hh) What general principles should apply to the management of all cases of drug-resistant TB?

**Response to treatment interruptions**

ii) For people receiving drug treatment for active TB who experience treatment interruptions, what approach to re-establishing appropriate treatment is the most effective in reducing mortality and morbidity?

**Infection control**

jj) For people in hospital who have active TB, what infection control measures are the most effective in preventing transmission of TB infection to others?

kk) For people who have active TB who are not in hospital but who are in congregate settings (for example residential homes or homeless shelters), what infection control measures are the most effective in preventing transmission of TB infection to others?

ll) For people who have active TB that is not suspected to be MDR-TB, and for whom isolation is indicated, what factors should determine the duration of isolation necessary to minimise the risk of infection to others? What is the optimum duration?

mm) For people who have active TB that is suspected to be MDR-TB, and for whom isolation is indicated, what factors should determine the duration of
isolation necessary to minimise the risk of infection to others? What is the optimum duration?

**Diagnosis of latent TB**

nn) Which diagnostic strategy is most effective in establishing an accurate diagnosis of latent TB in children?

oo) Which diagnostic strategy is most effective in establishing an accurate diagnosis of latent TB in people who are immunocompromised or at risk from immunosuppression?

pp) Which diagnostic strategy is most effective in establishing an accurate diagnosis of latent TB in people who are recent arrivals from countries with a high incidence of TB?

**Treatment of latent TB**

qq) According to their risk factors, which people with either latent TB infection or in close contact with people who have active TB should receive drug treatment to prevent the development of active TB?

rr) For people with latent TB infection, is a drug treatment regimen effective in preventing the development of active TB in comparison with placebo? If so, which regimen is the most effective in preventing the development of active TB?

**5.5.2 Areas to be developed by the Centre for Public Health Excellence**

**BCG vaccination uptake**

ss) Which strategies and interventions are effective and cost effective in increasing the uptake of BCG vaccination among people at increased risk of developing active or latent TB?

tt) What are the barriers to uptake of BCG vaccination among people at increased risk of developing active or latent TB?
Promoting the uptake of, and improving adherence to, treatment for people with active and latent TB

uu) Which strategies and interventions are effective and cost effective in promoting the uptake of, and improving adherence to, treatment for people with active and latent TB?

vv) What are the barriers to uptake and adherence to treatment for people with active and latent TB?

Information, education and support

ww) What information, education or other support-based interventions are currently used in practice to support the diagnosis, treatment and management of TB?

xx) How effective and cost effective are strategies and interventions aimed at providing and delivering information and education about the symptoms and risk of TB, clinical management of the illness and broader social support to people affected by TB?

Service delivery and configuration

yy) What are the optimal service models for configuring and delivering TB services – in terms of intermediate (‘process’) and final service outcomes, clinical outcomes, and costs – taking into account the differing requirements posed by:

- differences in incidence across areas and regions
- active and latent TB
- drug-resistant TB.

5.6 Economic aspects

Developers will take into account clinical and public health effectiveness and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate.

The preferred unit of effectiveness is the quality-adjusted life year (QALY). The costs considered in a clinical cost-effectiveness review will usually only be from an NHS
and personal social services (PSS) perspective. The costs considered in a public health cost-effectiveness review will usually only be from a public sector perspective, as well as the perspective of the department that administers the interventions.

Further detail on the methods can be found in 'The guidelines manual' and 'Methods for development of NICE public health guidance (third edition, 2012)' (see 'Further information').

5.7 Status

5.7.1 Scope
This is the final scope.

5.7.2 Timing
The development of the guidance recommendations will begin in February 2013.

6 Related NICE guidance

6.1 Published guidance

6.1.1 NICE guidance to be updated
This guidance will update and replace the following NICE guidance.

Tuberculosis. NICE clinical guideline 117 (2011).

6.1.2 Other related NICE guidance

Infection control. NICE clinical guideline 139 (2012).
Medicines adherence. NICE clinical guideline 76 (2009).
6.2  **Guidance under development**

NICE is currently developing the following related guidance (details available from the NICE website).

Xpert MTB/RIF assay (and alternative technologies identified during scoping). NICE Diagnostics Assessment Programme guidance. Status: this topic has been paused. The Health Technology Assessment (HTA) programme at the National Institute for Health Research (NIHR) has commissioned a project in which there is significant overlap with the planned scope of the Diagnostic Guidance. The topic has therefore been paused and any decision to proceed with the topic will depend on the outcome of the NIHR project.

7  **Further information**

Information on the guidance development process is provided in the following documents, available from the NICE website.

The [Centre for Clinical Practice's guideline development process and methods](https://www.nice.org.uk/guidance).

The [Centre for Clinical Practice’s interim methods guide for developing service guidance 2013](https://www.nice.org.uk/guidance).


Information on the progress of the guidance will also be available from the [NICE website](https://www.nice.org.uk).
2. Scope for clinical guideline 117

1 Guideline title

Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update)

1.1 Short title

Tuberculosis (partial update)

2 The remit

The Department of Health has asked NICE: ‘To produce a short clinical guideline on interferon-gamma immunological testing for diagnosing latent TB (partial review of CG33).’

3 Clinical need for the guideline

3.1 Epidemiology

Tuberculosis (TB) is an infectious disease caused by the bacterium *Mycobacterium tuberculosis*, also known as ‘the tubercle bacillus’. TB commonly affects the lungs, but can also affect other parts of the body. The symptoms of TB are varied and depend on the site of infection. General symptoms may include fever, loss of appetite, weight loss, night sweats and tiredness. TB is usually spread by coughs, but prolonged close contact with a person with TB is usually necessary for infection to be passed on. It can take many years for a person infected with *M. Tuberculosis* to develop active TB.

Each year, 10 million people develop clinical TB and 2 million die as a result of the disease. An estimated 2 billion people, a third of the world's population, have been exposed to *M. tuberculosis*. These people may carry the infection in its latent form and have a lifelong risk of developing active TB disease. In England cases fell progressively until the mid 1980s but started to rise again in the early 1990s. In 2008 there were 8665 cases of
TB reported in the UK (13.8 per 100,000) and the London region accounted for 39% of cases (43.2 per 100,000).

Almost all cases of clinical TB in the UK contract the disease by breathing in infected respiratory droplets from a person with infectious respiratory active TB disease. The initial infection may:

- be eliminated
- remain clinically latent, where the person has no symptoms but the TB bacteria remain in the body, or
- progress to active TB over the following weeks or months.

In people with latent TB, 10–15% of adults will go on to develop active TB at some point in their lives and the risk in children may be much higher. However, in people who are immunocompromised, the chance of developing active TB within 5 years of infection is up to 50%. Detection of latent TB is therefore important in controlling the disease.

### 3.2 Current practice

NICE clinical guideline 33 (‘Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control’) recommends that, to diagnose latent TB:

- Mantoux testing should be performed in line with the Green Book\(^a\) those with positive results (or in whom Mantoux testing may be less reliable) should then be considered for interferon-gamma immunological testing, if available.

If testing is inconclusive, the person should be referred to a TB specialist.

The Health Protection Agency (HPA) recommends the use of interferon gamma tests (IGTs) to screen for latent TB before immunosuppressive therapy (such as anti-TNF-α treatment).

The HPA also recommends the use of interferon gamma release assay tests after a positive tuberculin skin test (also known as a Mantoux test) for new entrant screening.
As part of the 2-year review process for NICE clinical guideline 33, concerns were raised about the appropriateness of IGT use in current clinical practice. A partial update on the use of IGT in the diagnosis of latent TB is therefore needed.

4  The guideline

The guideline development process is described in detail on the NICE website (see section 6, ‘Further information’).

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

4.1  Population

4.1.1  Groups that will be covered

Adults and children (children up to the age of 18 years of age will be covered as a separate group) at increased risk of infection by *M. tuberculosis* complex (*M. tuberculosis, M. africanum, M. bovis*), specifically if they:

- have arrived or returned from high-prevalence countries within the last 5 years
- were born in high prevalence countries
- live with people diagnosed with active TB
- have close contact with people diagnosed with active TB, for example at school or work
- are homeless and/or problem drug users
- are, or have a recently been, a prisoner.

Adults and children (children up to the age of 18 years will be covered as separate group) who are immunocompromised because of:
• prolonged steroid use (equivalent to 15 mg prednisolone daily for at least 1 month)
• TNF-α antagonists like infliximab and etanercept
• anti-rejection therapy such as cyclosporin, various cytotoxic treatments and some treatments for inflammatory bowel disease, such as azathioprine
• the use of immunosuppression-causing medication
• co morbid states that affect the immune system, for example HIV, chronic renal disease, many haematological and solid cancers, and diabetes.

4.1.2 Groups that will not be covered
Adults and children diagnosed with clinical disease caused by *Mycobacterium M. tuberculosis* complex (*M. tuberculosis*, *M. africanum*, *M. bovis*), including those with HIV.

Adults and children diagnosed with other infections caused by non-tuberculous mycobacteria, for example leprosy, *M. avium* complex and other opportunist mycobacteria.

4.2 Healthcare setting
Primary, secondary and tertiary care NHS settings, including specialist services like surgical transplant units, specialist cancer services, blood and bone marrow transplant units and specialised rheumatology units.

Occupational health departments within the NHS.

Prisons, community based centres and schools.

4.3 Clinical management

4.3.1 Key clinical issues that will be covered
Diagnosis of latent TB using *M. tuberculosis*-specific antigens (ESAT-6, CFP-10, and TB7.7) interferon gamma release assays (IGTs). The following commercially available assays will be reviewed:

• QuantiFERON-TB Gold In-Tube
• QuantiFERON-TB Gold
Appendix B: Guideline scopes

T-SPOT.TB.

The diagnostic utility of these assays, alone or in combination with a tuberculin skin test, will be compared with tuberculin skin test alone.

4.3.2 Clinical issues that will not be covered

Diagnosis of latent TB using tuberculin skin tests alone, unless as a comparator for IGTs.

Diagnosis of latent TB using purified protein derivative based IGTs.

Diagnosis of active TB.

Treatment of TB.

4.4 Main outcomes

The diagnostic utility of IGTs, either alone or in combination with tuberculin skin tests, and the threshold value for a positive diagnosis of latent TB.

The relationship between diagnostic accuracy of comparator strategies and TB exposure and/or BCG vaccination, including the degree of concordance between tuberculin skin tests and IGTs.

The value of IGTs in predicting the subsequent development of potential active TB.

The acceptability of diagnostic strategies, such as convenience, among relevant populations.

Adverse events. For example allergic reactions to various tests

Health-related quality of life.

Resource use and cost.

4.5 Economic aspects

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative tests. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the
costs considered will usually be only from an NHS and personal social services (PSS) perspective. Further detail on the methods can be found in ‘The guidelines manual’ (see ‘Further information’).

4.6 Status

4.6.1 Scope

This is the final version of the scope.

4.6.2 Timing

The development of the guideline recommendations will begin in February 2010.

5 Related NICE guidance

5.1 NICE guidance to be updated

This guideline will update and partially replace the following NICE guidance:


5.2 Guidance under development


6 Further information

Information on the guideline development process is provided in:

- ‘How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS'
- ‘The guidelines manual’.

These are available from the NICE website (www.nice.org.uk/guidelinesmanual). Information on the progress of the guideline will also be available from the NICE website (www.nice.org.uk).
Appendix B: Guideline scopes
3. Scope for clinical guideline 33

1. Guideline title
   Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control.

   1.1 Short title
   Tuberculosis

2. Background
   The National Institute for Clinical Excellence (‘NICE’ or ‘the Institute’) has commissioned the National Collaborating Centre for Chronic Conditions to develop a clinical guideline on tuberculosis (TB) for use in the NHS in England and Wales. This follows referral of the topic by the Department of Health and Welsh Assembly Government (see Appendix). The guideline will provide recommendations for good practice that are based on the best available evidence of clinical and cost effectiveness.

   The Institute’s clinical guidelines will support the implementation of National Service Frameworks (NSFs) in those aspects of care where a Framework has been published. The statements in each NSF reflect the evidence that was used at the time the Framework was prepared. The clinical guidelines and technology appraisals published by the Institute after an NSF has been issued will have the effect of updating the Framework.

4.3 Clinical need for the guideline
   1. Most cases of TB are potentially preventable by comprehensive application of public health measures and when clinical disease does occur, almost all cases can be cured if treated properly.

   2. However, tuberculosis continues to increase in England and Wales at an annual rate of approximately 5%, increasing from a low of approximately 5000 cases in 1987 to nearly 7000 in 2002.

   3. The previous evidence-based guidelines on chemotherapy and management (1998) and control and prevention of tuberculosis (2000) (see References)
from the Joint Tuberculosis Committee of the British Thoracic Society, will be respectively 7 and 5 years old in 2005, and need revision in light of advances in diagnosis and management, and newer data. This will however be a single guideline document.

A 4.4 The guideline
The guideline development process is described in detail in three booklets that are available from the NICE website (see ‘Further information’). The Guideline Development Process – Information for Stakeholders describes how organisations can become involved in the development of a guideline.

This document is the scope. It defines exactly what this guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health and Welsh Assembly Government (see Appendix).

The areas that will be addressed by the guideline are described in the following sections.

B 4.5 Population

C 4.5.1 Groups that will be covered
1. People with clinical disease caused by Mycobacterium tuberculosis complex (Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis), including people with HIV.

2. People with latent infection with Mycobacterium tuberculosis complex but not clinical disease, including people with HIV.

3. People at increased risk of infection by Mycobacterium tuberculosis complex (e.g. recent arrivals and returns, household contacts of respiratory TB, street homeless, HIV infected persons).

4. Adults and children. Single combined searches will be performed, except for specific evidence for children in the areas of chemoprophylaxis regimen and chemotherapy for respiratory and meningeal TB.
5. TB in specific settings: prisons, schools, schoolteachers and others working with children

6. M Bovis will be considered only insofar as it relates directly to humans.

D **4.5.2 Groups that will not be covered**

1. People with other mycobacterial infections (Leprosy, M. avium complex and other opportunist mycobacteria)

2. Treatment of TB in sites other than pulmonary, meningeal, peripheral lymph nodes, spine, pericardial, disseminated including miliary, and genitourinary.

3. Intravenous drug users, pregnant women or those planning pregnancy, people with diabetes, liver disease, renal disease, mental illness or cognitive losses, people who are unconscious, and older people in long-term care. Renal insufficiency will be considered in terms of treatment and chemoprophylaxis.

4. Social determinants of risk (the responsibility of non-NHS agencies)

5. Service models will be excluded from this guideline, except for areas in the public health topics where the GDG agree that the needs assessment indicates a priority for guidance to inform effective practice.

E **4.6 Healthcare setting**

1. Primary and secondary care NHS settings

2. Occupational health within the NHS: infection control, staff protection

3. Public Health (including the Health Protection Agency)

F **4.7 Areas to be covered**

G **Clinical management: Diagnosis and management of TB disease**

1. diagnosis of clinical disease (respiratory and non-respiratory sites) including:

   - people with HIV
   - clinical suspicion of disease
radiological patterns (respiratory TB only)
microbiological confirmation, excluding liquid culture
molecular testing will not be included in this clinical section.

2. management of clinical TB disease: pulmonary, meningeal, peripheral lymph nodes, bone and joints, pericarditis, disseminated tuberculosis and other sites (including genitourinary).

3. diagnosis and management of latent infection without disease, including people with HIV, and prophylaxis for adults and children

4. diagnosis and referral of multiple drug resistance and isolated and combined resistances, but excluding treatment.

5. Tests and follow-up after treatment completion

6. The role of Directly Observed Therapy (DOT).

7. Approaches to promote concordance.

H Public health measures: Prevention and control of TB
h) BCG vaccination of uninfected, at-risk groups, including neonates.

i) Contact tracing services in preventing spread of infection (including *M Bovis* in human contacts of cattle with tuberculosis).

j) Finding active cases from groups at increased risk of infection

k) Investigating outbreaks

l) Prevention and control of TB in specific settings (i.e. prisons, schools, schoolteachers and others working with children).

m) Measures to ensure that those with clinical disease (other than Multi-drug resistant TB) do not infect other patients or NHS staff are included.

n) Rapid diagnostic techniques: liquid culture and molecular testing.
Appendix B: Guideline scopes

o) Notification and enhanced surveillance, including legal obligations and outcome monitoring.

I 4.8 Audit support within guideline
1. The guideline will include Level 1 clinical audit criteria.

J 4.9 Status

K 4.9.1 Scope
This is the final draft of the Scope.

L 4.9.2 Guideline
The development of the guideline recommendations will begin in the first quarter of 2004.

M 4.10 Further information
Information on the guideline development process is provided in:

The Guideline Development Process – Information for the Public and the NHS

The Guideline Development Process – Information for Stakeholders


These booklets are available as PDF files from the NICE website (www.nice.org.uk). Information on the progress of the guideline will also be available from the website.

N Referral from the Department of Health and Welsh Assembly Government
The Department of Health and the Welsh Assembly Government asked the National Institute for Clinical Excellence:

“To prepare clinical guidelines for the NHS in England and Wales on the clinical management and diagnosis of, and measures to prevent and control, tuberculosis to replace the current guidance from the British Thoracic Society.”
Scopes for NICE clinical guideline update 2015, NICE clinical guideline 117 & NICE clinical guideline 33